Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) insider Milos Miljkovic sold 948 shares of Cartesian Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total transaction of $15,954.84. Following the transaction, the insider now directly owns 35,393 shares in the company, valued at $595,664.19. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Milos Miljkovic also recently made the following trade(s):

• On Friday, January 3rd, Milos Miljkovic sold 932 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.72, for a total transaction of $15,583.04.
• On Thursday, November 14th, Milos Miljkovic sold 35,000 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.13, for a total value of $564,550.00.

Cartesian Therapeutics Price Performance

Shares of NASDAQ RNAC traded down $0.47 during mid-day trading on Tuesday, hitting $17.16. 105,686 shares of the stock traded hands, compared to its average volume of 132,021. The firm has a 50 day simple moving average of $19.32 and a two-hundred day simple moving average of $18.19. The company has a market cap of $436.12 million, a PE ratio of -0.32 and a beta of 0.56. Cartesian Therapeutics, Inc. has a twelve month low of $11.66 and a twelve month high of $41.87.

Analysts Set New Price Targets

Several analysts have issued reports on RNAC shares. BTIG Research assumed coverage on shares of Cartesian Therapeutics in a research report on Thursday, December 19th. They set a "buy" rating and a $42.00 price target on the stock. Cantor Fitzgerald upgraded shares of Cartesian Therapeutics to a "hold" rating in a research report on Monday, December 2nd. Needham & Company LLC restated a "buy" rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a research note on Tuesday, December 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $45.00 price target (up from $41.00) on shares of Cartesian Therapeutics in a research note on Wednesday, December 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Cartesian Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $42.86.

Institutional Trading of Cartesian Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RNAC. BNP Paribas Financial Markets increased its stake in shares of Cartesian Therapeutics by 122.5% in the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company's stock valued at $27,000 after buying an additional 909 shares during the period. Point72 DIFC Ltd acquired a new position in Cartesian Therapeutics in the second quarter valued at $47,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Cartesian Therapeutics in the second quarter worth approximately $49,000. Barclays PLC lifted its position in shares of Cartesian Therapeutics by 208.6% during the 3rd quarter. Barclays PLC now owns 11,611 shares of the company's stock valued at $188,000 after acquiring an additional 7,849 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Cartesian Therapeutics during the second quarter valued at about $351,000. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.